Castle Biosciences, Inc. (Nasdaq: CSTL) has announced new data highlighting a substantial reduction in healthcare management costs and an enhancement in the quality of life for patients with Barrett’s esophagus (BE) when their care is guided by the TissueCypher test. This data was presented at the 2024 American College of Gastroenterology (ACG 2024) Annual Scientific Meeting, taking place from October 25-30 in Philadelphia.
“Our team from four academic medical centers collaborated to assess the cost-effectiveness of TissueCypher in managing Barrett’s esophagus (BE),” said Dr. Cadman L. Leggett from the Mayo Clinic in Rochester, Minnesota. “Using a Markov decision and microsimulation model with 10,000 patients, we found that managing BE could save $17 million if patients identified by TissueCypher as at risk for cancer progression received endoscopic eradication therapy (EET). More importantly, TissueCypher-guided care reduced the incidence of esophageal cancer progression by 58.4% among patients with intermediate or high-risk scores who underwent EET.”
At ACG 2024, over 5,100 scientific abstracts will be presented, but only a select few, including Castle’s TissueCypher poster, received a Presidential Poster Award, recognizing exceptional research. Details about Castle’s award-winning poster are as follows:
P3924. (S702). Risk-Aligned Management Guided by the Tissue Systems Pathology Test Can Improve Health Outcomes in Barrett’s Esophagus and Reduce Healthcare-Associated Costs.
Key Takeaways:
- This study examined the cost-effectiveness of TissueCypher-guided management for BE patients.
- Results showed that the test significantly reduces management costs by de-escalating care for low-risk patients (e.g., less unnecessary surveillance and EET) and escalating care for higher-risk patients (e.g., earlier EET to prevent high-grade dysplasia or esophageal adenocarcinoma).
- Beyond cost savings, the study indicates that TissueCypher-guided care improves patient quality of life and health outcomes, leading to a 58.4% reduction in high-grade dysplasia/esophageal adenocarcinoma incidence and a 59.6% decrease in EAC-related deaths.
To view the full poster, visit the ACG 2024 ePoster Hall. For more about TissueCypher, visit Castle at booth 1083.
About TissueCypher® Barrett’s Esophagus Test
The TissueCypher Barrett’s Esophagus test is a precision medicine tool designed to predict the future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus. It is indicated for patients with endoscopic biopsy-confirmed BE that is non-dysplastic (NDBE), indefinite for dysplasia (IND), or low-grade dysplasia (LGD). The test’s clinical performance is backed by 14 peer-reviewed publications from leading clinical centers worldwide. It received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) in March 2022. Learn more at Castle Biosciences.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company dedicated to improving health through innovative tests that guide patient care. The company aims to transform disease management with a patient-first approach for individuals, clinicians, employees, and investors.
Castle’s portfolio includes tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, along with active research and development for tests targeting other diseases with high clinical needs, such as those guiding systemic therapy for moderate-to-severe atopic dermatitis and psoriasis. For more information, visit Castle Biosciences and connect on LinkedIn, Facebook, X, and Instagram.
Trademarks: DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
